Operator: There is one more question that popped in the queue from Rachel Vatnsdal with JP Morgan. Your line is open.
Rachel Vatnsdal: Perfect. Thanks guys for taking the question. First up, we’ve previously talked about some of the uneven recoveries by geography. Last quarter, you noted that New York City was still not fully recovered, so can you just give us the latest update on the recovery there in New York? Then my follow-up is just on the analyst day this March, can you walk us through some of the topics that you plan on hitting on, any expectations for that? Thanks.
Sam Samad: Yes, thank you, Rachel, for the question – this is Sam. In terms of the geography, I think it’s consistent with what we said before, and let me repeat what we said because we haven’t seen really a major change in the dynamic yet. We are back to pre-pandemic levels and above across most geographies, the notable exception being the east, where New York City, I think we’ve seen roughly 3% to 5% outflow from the city in terms of population, 3% to 5% of the population leaving the city. We haven’t seen that fully come back yet, even though the city is much more vibrant and there’s more activity. But I don’t think in terms of people coming back and getting health care in New York City, I don’t think it’s back to where it was pre-pandemic by any means.
The other thing we look at is ridership on public transportation as an indicator, as a key metric to see how is that also coming back, and it’s still about 35% or so below pre-pandemic levels in terms of ridership, based on the last data points that we got. The punch line here being that the east is still lagging, but everywhere else is above pre-pandemic levels in terms of utilization.
Jim Davis: Yes, and then Rachel, thanks for the question on investor day. I think there’s really four broad topics that we’re going to talk about. First around growth, we’ll go deep on what we’re doing from an oncology and genomic sequencing standpoint. We’ll give you a lot more color on our consumer initiated testing business, the progress we’re making and why we continue to be excited about that, and then we’ll also address the core part of this business, which is serving physicians, serving health systems, and what we’re doing to continue to drive growth in those segments. Finally and as always, we’ll address what we’re doing to improve the customer experience and drive productivity in this business. It’s a never-ending part of what we do and we continue to drive productivity, and we’ll give you our plans for ’23 and beyond.
Finally, just as a reminder, it is March 16, it will be at the New York Stock Exchange, and we’ll obviously provide our long term outlook as part of that session.
Operator: I’m showing no further questions in the queue.
Jim Davis: Okay, so I wanted to thank everybody for joining the call today. We look forward to seeing you all on March 16 at the New York Stock Exchange, and have a great afternoon. Thanks everyone.
Sam Samad: Thank you everybody.
Operator: Thank you for participating in the Quest Diagnostics fourth quarter and full year 2022 conference call. A transcript of prepared remarks on this call will be posted later today on Quest Diagnostics’ website at www.questdiagnostics.com. A replay of the call may be accessed online at www.questdiagnostics.com/investor, or by phone at 203-369-3056 for international callers, or 888-566-0498 for domestic callers. Telephone replays will be available from approximately 10:30 am Eastern time on February 2, 2023 until midnight Eastern time on February 16, 2023. Goodbye.
